In a mouse model of lymphoma, it was verified that the injection of genetically engineered bacterium SLIC‐2 (co‐expressing anti‐PD‐L1nb and anti‐CTLA‐4 nb in equal amounts) resulted in better therapeutic efficacy than SLIC:PD‐L1nb alone or SLIC:CTLA‐4 nb alone.[112] Contributed by them, an increase in activated T‐cells (CD8+IFNγ+TNFα+) and a decrease in regulatory T‐cells (CD4+ FOXP3+) were accessible. Here, CTLA4 is linked to lymphoma.